These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study. Wright PM; Hart P; Lau M; Sharma ML; Gruenke L; Fisher DM Anesthesiology; 1994 Jul; 81(1):59-68; discussion 27A. PubMed ID: 7913801 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. Sorooshian SS; Stafford MA; Eastwood NB; Boyd AH; Hull CJ; Wright PM Anesthesiology; 1996 May; 84(5):1083-91. PubMed ID: 8624002 [TBL] [Abstract][Full Text] [Related]
30. Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. Parker CJ; Jones JE; Hunter JM Br J Anaesth; 1988 Nov; 61(5):531-40. PubMed ID: 3207525 [TBL] [Abstract][Full Text] [Related]
31. Cerebrospinal fluid concentrations of atracurium, laudanosine and vecuronium following clinical subarachnoid hemorrhage. Tassonyi E; Fathi M; Hughes GJ; Chiodini F; Bertrand D; Muller D; Fuchs-Buder T Acta Anaesthesiol Scand; 2002 Nov; 46(10):1236-41. PubMed ID: 12421196 [TBL] [Abstract][Full Text] [Related]
32. Atracurium resistance in a critically Ill patient. Tschida SJ; Hoey LL; Nahum A; Vance-Bryan K Pharmacotherapy; 1995; 15(4):533-9. PubMed ID: 7479210 [TBL] [Abstract][Full Text] [Related]
33. Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. Bergeron L; Bevan DR; Berrill A; Kahwaji R; Varin F Anesthesiology; 2001 Aug; 95(2):314-23. PubMed ID: 11506100 [TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacokinetics of the newer neuromuscular blocking drugs. Atherton DP; Hunter JM Clin Pharmacokinet; 1999 Mar; 36(3):169-89. PubMed ID: 10223167 [TBL] [Abstract][Full Text] [Related]
35. The infusion requirements and recovery characteristics of cisatracurium or atracurium in intensive care patients. Pearson AJ; Harper NJ; Pollard BJ Intensive Care Med; 1996 Jul; 22(7):694-8. PubMed ID: 8844237 [TBL] [Abstract][Full Text] [Related]
36. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Prielipp RC; Coursin DB; Scuderi PE; Bowton DL; Ford SR; Cardenas VJ; Vender J; Howard D; Casale EJ; Murray MJ Anesth Analg; 1995 Jul; 81(1):3-12. PubMed ID: 7598277 [TBL] [Abstract][Full Text] [Related]
37. Newer neuromuscular blocking agents: how do they compare with established agents? Sparr HJ; Beaufort TM; Fuchs-Buder T Drugs; 2001; 61(7):919-42. PubMed ID: 11434449 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic analysis of the time course of effect of atracurium. Warwick NR; Graham GG; Torda TA Clin Pharmacol Ther; 1995 Apr; 57(4):390-7. PubMed ID: 7712666 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and pharmacodynamics of atracurium in infants and children. Fisher DM; Canfell PC; Spellman MJ; Miller RD Anesthesiology; 1990 Jul; 73(1):33-7. PubMed ID: 2360737 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration. Donati F; Gill SS; Bevan DR; Ducharme J; Theoret Y; Varin F Br J Anaesth; 1991 May; 66(5):557-61. PubMed ID: 2031815 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]